Analysts expect Sarepta Therapeutics Inc (NASDAQ:SRPT) to announce earnings per share (EPS) of ($0.67) for the current fiscal quarter, according to Zacks Investment Research. Nine analysts have issued estimates for Sarepta Therapeutics’ earnings, with estimates ranging from ($1.03) to ($0.32). Sarepta Therapeutics posted earnings per share of ($0.37) during the same quarter last year, which would indicate a negative year over year growth rate of 81.1%. The firm is expected to report its next quarterly earnings report on Thursday, March 7th.
On average, analysts expect that Sarepta Therapeutics will report full year earnings of ($1.94) per share for the current fiscal year, with EPS estimates ranging from ($2.30) to ($1.61). For the next fiscal year, analysts forecast that the firm will report earnings of ($1.89) per share, with EPS estimates ranging from ($2.96) to ($0.45). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that cover Sarepta Therapeutics.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, October 24th. The biotechnology company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.29). Sarepta Therapeutics had a negative net margin of 89.46% and a negative return on equity of 23.67%. The company had revenue of $78.49 million for the quarter, compared to analysts’ expectations of $78.84 million.
Shares of SRPT stock opened at $130.97 on Tuesday. Sarepta Therapeutics has a 1 year low of $50.68 and a 1 year high of $176.50. The company has a current ratio of 8.85, a quick ratio of 7.84 and a debt-to-equity ratio of 0.65. The company has a market cap of $8.65 billion, a price-to-earnings ratio of -79.86 and a beta of 1.84.
In other news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the stock in a transaction that occurred on Thursday, November 1st. The stock was sold at an average price of $140.50, for a total value of $936,713.50. Following the sale, the director now directly owns 126,534 shares in the company, valued at $17,778,027. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Douglas S. Ingram purchased 16,695 shares of Sarepta Therapeutics stock in a transaction dated Tuesday, October 30th. The stock was acquired at an average price of $120.39 per share, for a total transaction of $2,009,911.05. Following the completion of the acquisition, the chief executive officer now owns 412,811 shares of the company’s stock, valued at approximately $49,698,316.29. The disclosure for this purchase can be found here. Corporate insiders own 7.90% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of SRPT. First Quadrant L P CA purchased a new stake in shares of Sarepta Therapeutics in the third quarter worth approximately $130,000. Ffcm LLC purchased a new position in Sarepta Therapeutics during the 3rd quarter worth $162,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors purchased a new position in Sarepta Therapeutics during the 2nd quarter worth $185,000. Keybank National Association OH purchased a new position in Sarepta Therapeutics during the 2nd quarter worth $206,000. Finally, Advisory Research Inc. purchased a new position in Sarepta Therapeutics during the 3rd quarter worth $214,000. Hedge funds and other institutional investors own 90.85% of the company’s stock.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.